Restriction of Human Cytomegalovirus Infection by Galectin-9

J Virol. 2019 Jan 17;93(3):e01746-18. doi: 10.1128/JVI.01746-18. Print 2019 Feb 1.

Abstract

Human cytomegalovirus (HCMV) is a ubiquitous human herpesvirus. While HCMV infection is generally asymptomatic in the immunocompetent, it can have devastating consequences in those with compromised or underdeveloped immune systems, including transplant recipients and neonates. Galectins are a widely expressed protein family that have been demonstrated to modulate both antiviral immunity and regulate direct host-virus interactions. The potential for galectins to directly modulate HCMV infection has not previously been studied, and our results reveal that galectin-9 (Gal-9) can potently inhibit HCMV infection. Gal-9-mediated inhibition of HCMV was dependent upon its carbohydrate recognition domains and thus dependent on glycan interactions. Temperature shift studies revealed that Gal-9 specific inhibition was mediated primarily at the level of virus-cell fusion and not binding. Additionally, we found that during reactivation of HCMV in hematopoietic stem cell transplant (HSCT) patients soluble Gal-9 is upregulated. This study provides the first evidence for Gal-9 functioning as a potent antiviral defense effector molecule against HCMV infection and identifies it as a potential clinical candidate to restrict HCMV infections.IMPORTANCE Human cytomegalovirus (HCMV) continues to cause serious and often life-threatening disease in those with impaired or underdeveloped immune systems. This virus is able to infect and replicate in a wide range of human cell types, which enables the virus to spread to other individuals in a number of settings. Current antiviral drugs are associated with a significant toxicity profile, and there is no vaccine; these factors highlight a need to identify additional targets for the development of anti-HCMV therapies. We demonstrate for the first time that secretion of a member of the galectin family of proteins, galectin-9 (Gal-9), is upregulated during natural HCMV-reactivated infection and that this soluble cellular protein possesses a potent capacity to block HCMV infection by inhibiting virus entry into the host cell. Our findings support the possibility of harnessing the antiviral properties of Gal-9 to prevent HCMV infection and disease.

Keywords: cytomegalovirus; human herpesviruses; virus-host interactions.

MeSH terms

  • Adult
  • Antiviral Agents / metabolism
  • Case-Control Studies
  • Cells, Cultured
  • Cytomegalovirus / pathogenicity*
  • Cytomegalovirus Infections / metabolism
  • Cytomegalovirus Infections / prevention & control*
  • Cytomegalovirus Infections / virology
  • Fibroblasts / cytology
  • Fibroblasts / metabolism
  • Fibroblasts / virology
  • Galectins / metabolism*
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Prospective Studies
  • Transplant Recipients
  • Virus Activation*
  • Virus Internalization*
  • Virus Replication*

Substances

  • Antiviral Agents
  • Galectins
  • LGALS9 protein, human